Lysophosphatidic acid

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Originally, autotaxin was identified as a factor that stimulates cell proliferation. Later it was shown that it is indeed lysophosphatidic acid (LPA) catalysed by autotaxin, which releases lysophosphatidylcholine (LPC) from its substrate and signals via lysophospholipid receptors (LPAR) (Stand S 2018). Under physiological conditions, LPA negatively regulates autotaxin transcription. Lysophosphatidic acid induces growth factor-like responses, including stimulation of cell proliferation and chemotaxis.

General informationThis section has been translated automatically.

LPARs are expressed in all known cell types of the CNS, where they mediate basic cellular processes such as proliferation, differentiation, migration, chronic inflammation and cytoskeletal organization. Consequently, dysregulation of the LPA content can lead to a number of CNS and PNS disorders. These include chronic inflammatory or neuropathic pain, glioblastoma multiforme (GBM), hemorrhagic hydrocephalus, schizophrenia, multiple sclerosis, Alzheimer's disease, brain damage induced by the metabolic syndrome, and cerebral oedema induced by hepatic encephalopathy. It also plays a role in macular edema, in severe depressive disorders, in stress-induced psychiatric disorders, in alcohol- and HIV-induced brain damage, in pruritus and peripheral nerve injury. ATX inhibitors are in clinical phase III (Mr DR et al.2018; Fujino H et al. 2019).

LiteratureThis section has been translated automatically.

Fujino H et al (2019) Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterol 24:169.

Hegade VS et al (2019) Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver Int 39:967-975.

Mr DR et al (2018) Potential Therapeutic Applications for Inhibitors of Autotaxin, a Bioactive Lipid-Producing Lysophospholipase D, in Disorders Affecting the Nervous System. ACS Chem Neurosci 9:398-400.

Macias RIR et al (2018) Role of the placenta in serum autotaxin elevation during maternal cholestasis. On J Physiol Gastrointest Liver Physiol 315:G399-G407.

Robering JW et al (2019) Lysophosphatidic acid activates satellite glia cells and Schwann cells. Glia 67:999-1012.

Stand S (2018) Pruritus, Prurigo. In: Braun-Falco`s Dermatology, Venerology Allergology G. Plewig et al (Hrsg) Springer Verlag S 587

Authors

Last updated on: 29.10.2020